Loading stock data…
Omnicell, Inc. (OMCL)
$41.00+1.14 (+2.86%)
Market ClosedLast close Jul 24
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Omnicell, Inc. in the Healthcare sector is trading at $41.00 with a market capitalization of $1.9B. Wall Street consensus targets $61.29 (7 analysts), implying a +49.5% move over the next 12 months. The stock is currently 25% below its 52-week high of $55.00, remaining 2.2% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +49.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $309.88M↓ | $313.98M↑ | $310.63M↑ | $290.56M↑ | $269.67M |
| Gross Profit | $140.36M↑ | $130.32M↓ | $134.50M↑ | $127.68M↑ | $110.94M |
| Operating Income | $16.85M↑ | $415,000↓ | $8.24M↑ | $8.12M↑ | -$11.62M |
| Net Income | $11.36M↑ | -$2.03M↓ | $5.46M↓ | $5.64M↑ | -$7.02M |
Peer Comparison
JNJUNHPFE
Fundamentals
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the heal...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.91B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
95.20
Beta
Defensive asset. Lower volatility than the S&P 500.
0.96
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
1.63%
Volume
Today's trading volume
557,409
Recent News
2 Cash-Heavy Stocks to Target This Week and 1 We Turn Down
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.
Omnicell to Report Q2 Earnings: OmniSphere in Focus
OMCL heads into Q2 earnings with OmniSphere adoption, Connected Devices execution and recurring revenue growth ahead of July 30 results.
1 Healthcare Stock to Target This Week and 2 We Brush Off
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 13.3% over the past six months, topping the S&P 500 by 2.5 percentage points.
The Bull Case For Omnicell (OMCL) Could Change Following New President And ESOP Share Offering
Earlier this month, Omnicell filed a US$72.384 million shelf registration for 1,600,000 common shares tied to an ESOP-related offering and elevated Chief Operating Officer Nnamdi Njoku to President, while Randall Lipps remained Chief Executive Officer and Chairman. This combination of leadership evolution and employee-focused equity issuance may influence how investors assess Omnicell’s governance, culture, and long-term execution capacity. We’ll now examine how Njoku’s expanded leadership...
Should You Continue to Hold OMCL Stock in Your Portfolio Now?
Omnicell is advancing its autonomous pharmacy vision and expanding SaaS offerings, but tariffs and fierce competition could test its growth path.